Comparative study status on therapeutic effects of different treatments for recurrent hepatocellular carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

CAO Junqiu ,  LI Bo

Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

LI Bo, Email: cdhxlb@126.com

Keywords：

recurrent hepatocellular carcinoma; treatment; comparison of therapeutic effect

DOI：

10.7507/1007-9424.202008063

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the current comparison of the efficacy of different treatments for recurrent hepatocellular carcinoma.Method To search the literatures about the comparative studies on the efficacy of different treatments for recurrent hepatocellular carcinoma in recent years and analyze them.Results In the treatment of recurrent hepatocellular carcinoma, percutaneous arterial chemoembolization combined with radiofrequency ablation could improve the survival rate and tumor-free survival rate to some extent, compared with the single use of percutaneous arterial chemoembolization. In the short term, there was no difference in efficacy between radiofrequency ablation and surgical resection, but the local recurrence rate of radiofrequency ablation was higher than that of surgical resection group. Salvage liver transplantation offered potential opportunity to reduce the risk of recurrence and tended to improve long-term survival outcomes, but liver sources were scarce and costly. Conclusions At present, there is no systematic staging scheme and treatment system for recurrent hepatocellular carcinoma. At the same time, most studies are retrospective, and more prospective studies are needed to further explore the treatment of recurrent hepatocellular carcinoma.

Citation： CAO Junqiu, LI Bo. Comparative study status on therapeutic effects of different treatments for recurrent hepatocellular carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(5): 695-698. doi: 10.7507/1007-9424.202008063 Copy

1.	Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391(10127): 1301-1314.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	叢文銘, 吳孟超. 肝癌術后復發的發生機制及臨床病理學意義. 中國實用外科雜志, 2012, 32(10): 809-811.
4.	Saraswat VA, Pandey G, Shetty S. Treatment algorithms for man aging hepatocellular carcinoma. J Clin Exp Hepatol, 2014, 4(Suppl 3): 80-89.
5.	中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療規范 (2019 年版). 中國實用外科雜志, 2020, 40(2): 121-138.
6.	Yong CC, Tsai MC, Lin CC, et al. Comparison of salvage living donor liver transplantation and local regional therapy for recurrent hepatocellular carcinoma. World J Surg, 2016, 40(10): 2472-2480.
7.	Famularo S, Di Sandro S, Giani A, et al. Recurrence patterns after anatomic or parenchyma-sparing liver resection for hepatocellular carcinoma in a western population of cirrhotic patients. Ann Surg Oncol, 2018, 25(13): 3974-3981.
8.	Xiao H, Chen ZB, Jin HL, et al. Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Am J Transl Res, 2019, 11(3): 1864-1875.
9.	Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg, 2017, 104(11): 1433-1442.
10.	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822): 1245-1255.
11.	Choo SP, Tan WL, Goh BKP, et al. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer, 2016, 122(22): 3430-3446.
12.	Huan HB, Lau WY, Xia F, et al. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol, 2014, 20(39): 14505-14509.
13.	毛廷輝, 吳剛. 復發性肝癌靶向治療及免疫治療. 中國實用外科雜志, 2019, 39(10): 1048-1051.
14.	張耀軍, 陳敏山. 肝癌術后復發的多學科綜合治療. 中國實用外科雜志, 2019, 39(10): 1042-1044.
15.	Tham S, Cai M, Syn N, et al. Utility of TACE and RFA for unresectable recurrent HCC: inverse probability of treatment-weighted subgroup analyses of overall survival. HPB, 2019, 21(Supl 2): S240.
16.	Wang X, Liang H, Lu Z. Efficacy of transarterial chemo-embolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minim Invasive Ther Allied Technol, 2020, 29(6): 344-352.
17.	Chen R, Gan Y, Ge N, et al. Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within barcelona clinic liver cancer stage 0/A: a retrospective comparative study. J Vasc Interv Radiol, 2016, 27(12): 1829-1836.
18.	Koh PS, Chan AC, Cheung TT, et al. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford), 2016, 18(1): 72-78.
19.	莫嘉強, 何軍明, 刁競芳, 等. 超聲微創介入治療復發性肝癌的臨床療效及預后分析. 中國數字醫學, 2020, 15(4): 96-98.
20.	Wang C, Liao Y, Qiu J, et al. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol, 2020, 146(10): 2669-2680.
21.	舒強, 劉小玲, 楊小李, 等. 經導管肝動脈化療栓塞術聯合經皮微波消融治療復發性肝癌的預后分析. 中國普通外科雜志, 2020, 29(1): 11-18.
22.	Xia Y, Li J, Liu G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol, 2020, 6(2): 255-263.
23.	Feng Y, Wu H, Huang DQ, et al. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤5 cm) after initial curative resection. Eur Radiol, 2020, 30(11): 6357-6368.
24.	劉嘉龍, 黃登, 曹利, 等. 腹腔鏡肝切除術和射頻消融術治療復發性肝癌的前瞻性隨機對照研究(中期隨訪分析). 第三軍醫大學學報, 2019, 41(5): 467-472.
25.	譚增光, 馮樹開, 王軍, 等. 復發性小肝癌采用經皮肝穿刺射頻消融與再次肝切除的療效比較. 醫學理論與實踐, 2020, 33(11): 1790-1792.
26.	李春麗, 董巧云, 侯麗, 等. 二次切除手術與經皮射頻消融治療切除后復發性肝細胞肝癌的臨床療效和預后分析. 中國醫學裝備, 2019, 16(12): 47-51.
27.	張波濤, 崔智飛, 段希斌, 等. 射頻消融術和腹腔鏡肝切除術治療復發性肝癌的臨床療效及遠期生存情況分析. 癌癥進展, 2020, 18(5): 482-484, 499.
28.	陳康, 劉新宇, 滕煜憲, 等. 再次肝切除與射頻消融治療復發性肝癌療效對比研究. 中國實用外科雜志, 2019, 39(10): 1060-1064.
29.	Midorikawa Y, Takayama T, Moriguchi M, et al. Liver resection versus embolization for recurrent hepatocellular carcinoma. World J Surg, 2020, 44(1): 232-240.
30.	Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl, 2013, 19(4): 411-419.
31.	Hu Z, Zhou J, Xu X. et al Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS One, 2012, 7(5): e36587.
32.	Lim C, Shinkawa H, Hasegawa K, et al. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis. Liver Transpl, 2017, 23(12): 1553-1563.
33.	Ma KW, Chok KSH, She WH, et al. Defining optimal surgical treatment for recurrent hepatocellular carcinoma: A propensity score matched analysis. Liver Transpl, 2018, 24(8): 1062-1069.
34.	Guo Y, Tan EK, Syn NL, et al. Repeat liver resection versus salvage liver transplant for recurrent hepatocellular carcinoma: A propensity score-adjusted and -matched comparison analysis. Ann Hepatobiliary Pancreat Surg, 2019, 23(4): 305-312.
35.	Fang JZ, Xiang L, Hu YK, et al. Options for the treatment of intrahepatic recurrent hepatocellular carcinoma: Salvage liver transplantation or rehepatectomy? Clin Transplant, 2020, 34(5): e13831.
36.	高本見, 羅佳, 劉瑩, 等. 挽救性肝移植與再次肝切除治療術后復發性肝癌療效對比的 Meta 分析. 中國普通外科雜志, 2020, 29(1): 1-10.
37.	Hanyong S, Wanyee L, Siyuan F, et al. A prospective randomized controlled trial: comparison of two different methods of hepatectomy. Eur J Surg Oncol, 2015, 41(2): 243-248.
38.	Zhang J, Zhou ZG, Huang ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer, 2016, 35: 25.
39.	Onoe T, Yamaguchi M, Irei T, et al. Feasibility and efficacy of repeat laparoscopic liver resection for recurrent hepatocellular carcinoma. Surg Endosc, 2020, 34(10): 4574-4581.
40.	Cai W, Liu Z, Xiao Y, et al. Comparison of clinical outcomes of laparoscopic versus open surgery for recurrent hepatocellular carcinoma: a meta-analysis. Surg Endosc, 2019, 33(11): 3550-3557.
41.	Gon H, Kido M, Tanaka M, et al. Laparoscopic repeat hepatectomy is a more favorable treatment than open repeat hepatectomy for contralateral recurrent hepatocellular carcinoma cases. Surg Endosc, 2020. Online ahead of print.

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391(10127): 1301-1314.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. 叢文銘, 吳孟超. 肝癌術后復發的發生機制及臨床病理學意義. 中國實用外科雜志, 2012, 32(10): 809-811.
4. Saraswat VA, Pandey G, Shetty S. Treatment algorithms for man aging hepatocellular carcinoma. J Clin Exp Hepatol, 2014, 4(Suppl 3): 80-89.
5. 中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療規范 (2019 年版). 中國實用外科雜志, 2020, 40(2): 121-138.
6. Yong CC, Tsai MC, Lin CC, et al. Comparison of salvage living donor liver transplantation and local regional therapy for recurrent hepatocellular carcinoma. World J Surg, 2016, 40(10): 2472-2480.
7. Famularo S, Di Sandro S, Giani A, et al. Recurrence patterns after anatomic or parenchyma-sparing liver resection for hepatocellular carcinoma in a western population of cirrhotic patients. Ann Surg Oncol, 2018, 25(13): 3974-3981.
8. Xiao H, Chen ZB, Jin HL, et al. Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy. Am J Transl Res, 2019, 11(3): 1864-1875.
9. Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg, 2017, 104(11): 1433-1442.
10. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012, 379(9822): 1245-1255.
11. Choo SP, Tan WL, Goh BKP, et al. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer, 2016, 122(22): 3430-3446.
12. Huan HB, Lau WY, Xia F, et al. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol, 2014, 20(39): 14505-14509.
13. 毛廷輝, 吳剛. 復發性肝癌靶向治療及免疫治療. 中國實用外科雜志, 2019, 39(10): 1048-1051.
14. 張耀軍, 陳敏山. 肝癌術后復發的多學科綜合治療. 中國實用外科雜志, 2019, 39(10): 1042-1044.
15. Tham S, Cai M, Syn N, et al. Utility of TACE and RFA for unresectable recurrent HCC: inverse probability of treatment-weighted subgroup analyses of overall survival. HPB, 2019, 21(Supl 2): S240.
16. Wang X, Liang H, Lu Z. Efficacy of transarterial chemo-embolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minim Invasive Ther Allied Technol, 2020, 29(6): 344-352.
17. Chen R, Gan Y, Ge N, et al. Transarterial chemoembolization versus radiofrequency ablation for recurrent hepatocellular carcinoma after resection within barcelona clinic liver cancer stage 0/A: a retrospective comparative study. J Vasc Interv Radiol, 2016, 27(12): 1829-1836.
18. Koh PS, Chan AC, Cheung TT, et al. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford), 2016, 18(1): 72-78.
19. 莫嘉強, 何軍明, 刁競芳, 等. 超聲微創介入治療復發性肝癌的臨床療效及預后分析. 中國數字醫學, 2020, 15(4): 96-98.
20. Wang C, Liao Y, Qiu J, et al. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol, 2020, 146(10): 2669-2680.
21. 舒強, 劉小玲, 楊小李, 等. 經導管肝動脈化療栓塞術聯合經皮微波消融治療復發性肝癌的預后分析. 中國普通外科雜志, 2020, 29(1): 11-18.
22. Xia Y, Li J, Liu G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol, 2020, 6(2): 255-263.
23. Feng Y, Wu H, Huang DQ, et al. Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤5 cm) after initial curative resection. Eur Radiol, 2020, 30(11): 6357-6368.
24. 劉嘉龍, 黃登, 曹利, 等. 腹腔鏡肝切除術和射頻消融術治療復發性肝癌的前瞻性隨機對照研究(中期隨訪分析). 第三軍醫大學學報, 2019, 41(5): 467-472.
25. 譚增光, 馮樹開, 王軍, 等. 復發性小肝癌采用經皮肝穿刺射頻消融與再次肝切除的療效比較. 醫學理論與實踐, 2020, 33(11): 1790-1792.
26. 李春麗, 董巧云, 侯麗, 等. 二次切除手術與經皮射頻消融治療切除后復發性肝細胞肝癌的臨床療效和預后分析. 中國醫學裝備, 2019, 16(12): 47-51.
27. 張波濤, 崔智飛, 段希斌, 等. 射頻消融術和腹腔鏡肝切除術治療復發性肝癌的臨床療效及遠期生存情況分析. 癌癥進展, 2020, 18(5): 482-484, 499.
28. 陳康, 劉新宇, 滕煜憲, 等. 再次肝切除與射頻消融治療復發性肝癌療效對比研究. 中國實用外科雜志, 2019, 39(10): 1060-1064.
29. Midorikawa Y, Takayama T, Moriguchi M, et al. Liver resection versus embolization for recurrent hepatocellular carcinoma. World J Surg, 2020, 44(1): 232-240.
30. Chan AC, Chan SC, Chok KS, et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl, 2013, 19(4): 411-419.
31. Hu Z, Zhou J, Xu X. et al Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS One, 2012, 7(5): e36587.
32. Lim C, Shinkawa H, Hasegawa K, et al. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis. Liver Transpl, 2017, 23(12): 1553-1563.
33. Ma KW, Chok KSH, She WH, et al. Defining optimal surgical treatment for recurrent hepatocellular carcinoma: A propensity score matched analysis. Liver Transpl, 2018, 24(8): 1062-1069.
34. Guo Y, Tan EK, Syn NL, et al. Repeat liver resection versus salvage liver transplant for recurrent hepatocellular carcinoma: A propensity score-adjusted and -matched comparison analysis. Ann Hepatobiliary Pancreat Surg, 2019, 23(4): 305-312.
35. Fang JZ, Xiang L, Hu YK, et al. Options for the treatment of intrahepatic recurrent hepatocellular carcinoma: Salvage liver transplantation or rehepatectomy? Clin Transplant, 2020, 34(5): e13831.
36. 高本見, 羅佳, 劉瑩, 等. 挽救性肝移植與再次肝切除治療術后復發性肝癌療效對比的 Meta 分析. 中國普通外科雜志, 2020, 29(1): 1-10.
37. Hanyong S, Wanyee L, Siyuan F, et al. A prospective randomized controlled trial: comparison of two different methods of hepatectomy. Eur J Surg Oncol, 2015, 41(2): 243-248.
38. Zhang J, Zhou ZG, Huang ZX, et al. Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer, 2016, 35: 25.
39. Onoe T, Yamaguchi M, Irei T, et al. Feasibility and efficacy of repeat laparoscopic liver resection for recurrent hepatocellular carcinoma. Surg Endosc, 2020, 34(10): 4574-4581.
40. Cai W, Liu Z, Xiao Y, et al. Comparison of clinical outcomes of laparoscopic versus open surgery for recurrent hepatocellular carcinoma: a meta-analysis. Surg Endosc, 2019, 33(11): 3550-3557.
41. Gon H, Kido M, Tanaka M, et al. Laparoscopic repeat hepatectomy is a more favorable treatment than open repeat hepatectomy for contralateral recurrent hepatocellular carcinoma cases. Surg Endosc, 2020. Online ahead of print.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Comparative study status on therapeutic effects of different treatments for recurrent hepatocellular carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content